Seminars in Hematology

(The median citation count of Seminars in Hematology is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-07-01 to 2024-07-01.)
Memory-like natural killer cells for cancer immunotherapy53
Iron metabolism in infections: Focus on COVID-1950
Toward a pathophysiology inspired treatment of VEXAS syndrome43
Epidemiology of VITT34
Aplastic anemia: Pathophysiology33
Characteristic bone marrow findings in patients with UBA1 somatic mutations and VEXAS syndrome32
Treatment of vaccine-induced immune thrombotic thrombocytopenia (VITT)32
Platelet-activating anti-PF4 disorders: An overview30
Pathogenesis of vaccine-induced immune thrombotic thrombocytopenia (VITT)29
Thrombotic manifestations of VEXAS syndrome28
Mechanisms of cellular iron sensing, regulation of erythropoiesis and mitochondrial iron utilization25
Genetics of somatic auto-inflammatory disorders24
Clonal hematopoiesis and VEXAS syndrome: survival of the fittest clones?23
VEXAS within the spectrum of rheumatologic disease22
Monitoring MRD in ALL: Methodologies, technical aspects and optimal time points for measurement21
Modulating NK cell metabolism for cancer immunotherapy20
Shaping the bone through iron and iron-related proteins18
20 years of Hepcidin: How far we have come17
Genetic and epigenetic modification of human primary NK cells for enhanced antitumor activity17
VEXAS syndrome: An inflammatory and hematologic disease15
Laboratory testing for VITT antibodies13
Improving CAR T-cells: The next generation13
Role of blinatumomab, inotuzumab, and CAR T-cells: Which to choose and how to sequence for patients with relapsed disease11
Natural killer cell engineering – a new hope for cancer immunotherapy11
Longitudinal Aspects of VITT11
TET-dioxygenase deficiency in oncogenesis and its targeting for tumor-selective therapeutics10
Report of consensus panel 1 from the 11th International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-naïve patients10
NK cells as adoptive cellular therapy for hematological malignancies: Advantages and hurdles10
Pharmacogenomics and ALL treatment: How to optimize therapy10
Applications of virus-specific T cell therapies post-BMT10
Immunosuppressive therapy in severe aplastic anemia9
Clonality in immune aplastic anemia: Mechanisms of immune escape or malignant transformation9
Looking beyond VEXAS: Coexistence of undifferentiated systemic autoinflammatory disease and myelodysplastic syndrome9
Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteria9
DNA methylation inhibition in myeloma: Experience from a phase 1b study of low-dose continuous azacitidine in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multipl9
Selection of allogeneic hematopoietic cell transplant donors to optimize natural killer cell alloreactivity8
Extranodal natural killer/T-cell lymphoma: An overview on pathology and clinical management7
The epidemiology of Waldenström macroglobulinemia7
Epidemiology and etiology of diffuse large B-cell lymphoma7
The evolution of epigenetic therapy in myelodysplastic syndromes and acute myeloid leukemia7
Place of care manufacturing of chimeric antigen receptor cells: Opportunities and challenges7
The role of viruses in HIV-associated lymphomas7
Hemolytic paroxysmal nocturnal hemoglobinuria: 20 years of medical progress7
The spectrum of somatic mutations in large granular lymphocyte leukemia, rheumatoid arthritis, and Felty's syndrome7
Philadelphia chromosome positive acute lymphoblastic leukemia in adults: Therapeutic options and dilemmas in 20207
A pilot clinical trial of oral tetrahydrouridine/decitabine for noncytotoxic epigenetic therapy of chemoresistant lymphoid malignancies7
Diagnosis and management of adult T-cell leukemia/lymphoma6
Optimal approach to the treatment of young adults with acute lymphoblastic leukemia in 20206
SARS-CoV-2 vaccine-induced humoral and cellular immunity in patients with hematologic malignancies6
Iron and erythropoiesis: A mutual alliance5
Management of ALCL and other CD30+ peripheral T-cell lymphomas with a focus on Brentuximab vedotin5
Report of Consensus Panel 3 from the 11th International workshop on Waldenström's Macroglobulinemia: Recommendations for molecular diagnosis in Waldenström's Macroglobulinemia5
Clinical picture of VITT5
Advances in understanding the crosstalk between mother and fetus on iron utilization5
The challenge to further improvements in survival of patients with T-ALL: Current treatments and new insights from disease pathogenesis5
Somatic compensation of inherited bone marrow failure5
Somatic mutations and clonal expansions in paroxysmal nocturnal hemoglobinuria5
Epigenetic modifier directed therapeutics to unleash healthy genes in unhealthy cells5
Transforming CLL management with immunotherapy: Investigating the potential of CAR T-cells and bispecific antibodies4
Hepatitis C virus-associated B-cell lymphomas: The importance of the new direct antiviral agent therapy4
Clinical manifestations of clonal hematopoiesis: What has SF3B1-mutant MDS taught us?4
TET2 mutation as prototypic clonal hematopoiesis lesion4
Current challenges and new approaches to implementing optimal management of sickle cell disease in sub-Saharan Africa4
Infectious complications of chimeric antigen receptor (CAR) T-cell therapies4
Aplastic anemia: Quo vadis?4
Epigenetic activities in erythroid cell gene regulation4
Somatic mutations in VEXAS Syndrome and Erdheim-Chester disease: Inflammatory myeloid diseases4
Novel therapies targeting cutaneous T cell lymphomas and their microenvironment4
Cell senescence and malignant transformation in the inherited bone marrow failure syndromes: Overlapping pathophysiology with therapeutic implications4
Vaccine-induced immune thrombotic thrombocytopenia (VITT)4
Clinical applications of circulating tumor DNA in central nervous system lymphoma4
Somatic mutations in acquired pure red cell aplasia4
Clonal dynamics of hematopoietic stem cell compartment in aplastic anemia4
Management of Angioimmunoblastic T-Cell Lymphoma (AITL) and other T Follicular Helper Cell lymphomas (TFH PTCL)4
Gene editing for sickle cell disease and transfusion dependent thalassemias- A cure within reach4
Challenges and opportunities of CAR T-cell therapies for CLL3
Primary and secondary central nervous system mature T- and NK-cell lymphomas3
The evolution of NK cell immunotherapy for hematologic malignancies: A historical and contemporary perspective3
The natural killer cell immunotherapy platform: An overview of the landscape of clinical trials in liquid and solid tumors3
Second-line treatment of diffuse large B‐cell lymphoma: Evolution of options3
Report of consensus panel 5 from the 11th international workshop on Waldenstrom's macroglobulinemia on COVID-19 prophylaxis and management3
Palliative care needs of patients with hematologic malignancies and family caregivers and challenges of palliative care provision in Asia: A review of evidence3
Mendelian inheritance of anemia due to disturbed iron homeostasis3
Prognosis and risk stratification of peripheral T-cell lymphomas3
New approaches to the treatment of older adults with acute lymphoblastic leukemia3
Report of consensus panel 2 from the 11th international workshop on Waldenström's macroglobulinemia on the management of relapsed or refractory WM patients3
Molecularly targeted therapies for relapsed and refractory peripheral T-cell lymphomas2
Role of the tumor microenvironment in CLL pathogenesis2
Highlights of the 11th International Workshop on Waldenstrom's Macroglobulinemia: What we learned, and how it will impact scientific discovery and patient care2
Access to essential therapy for sickle cell disease in Africa: Experience from a national program in Ghana2
DLBCL arising from indolent lymphomas: How are they different?2
Epigenetic regulation of hemoglobin switching in non-human primates2
Biological heterogeneity in diffuse large B-cell lymphoma2
Inequalities in access to treatment in Argentina: Differences in management of CLL and multiple myeloma?2
Clonal hematopoiesis and autoimmunity2
The psychiatric and psychological sequelae of vaccine-induced immune thrombotic thrombocytopenia (VITT)2